{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:54:27Z","timestamp":1793066067855,"version":"4.5.0"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R21CA259158"],"award-info":[{"award-number":["R21CA259158"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R37CA291976"],"award-info":[{"award-number":["R37CA291976"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["K22CA263783"],"award-info":[{"award-number":["K22CA263783"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P01CA278375"],"award-info":[{"award-number":["P01CA278375"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA086862"],"award-info":[{"award-number":["P30CA086862"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSG-23-1149466-01-CDP"],"award-info":[{"award-number":["RSG-23-1149466-01-CDP"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P30GM145398"],"award-info":[{"award-number":["P30GM145398"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P30GM154633"],"award-info":[{"award-number":["P30GM154633"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["CA220729P1"],"award-info":[{"award-number":["CA220729P1"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>High-grade serous carcinoma tumours present poor survival rates, often associated with immunologically excluded environments driven by hypoxia and extensive extracellular matrix remodelling that disrupt tumour-stromal-immune interactions. Current experimental models fail to fully capture these microenvironmental features, limiting understanding of tumour-immune dynamics and drug development. Here, we present bioengineered patient-derived tumour-immune models to mimic physiologically relevant oxygen levels and extracellular matrix remodelling. Cancer cells are co-cultured with cancer-associated fibroblasts within human plasma-3D matrices or grown on decellularized human ovaries. Immune cells are either included within the 3D constructs to study multi-cellular interactions or challenged to infiltrate the matrices. We demonstrate that intratumoural hypoxia acts as a friend and a foe enhancing the activation and cytotoxicity of CD8\u2009+\u2009T cells while inducing stromal\/matrix dysregulation associated with impaired immune infiltration. Targeting TGF-\u03b2 signalling attenuates the hypoxia-driven stromal-mediated immune exclusion. These relevant models may aid the development of targeted therapies to transform immunologically cold tumours into immunogenic to benefit female patients.<\/jats:p>","DOI":"10.1038\/s41467-026-75262-8","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T18:04:53Z","timestamp":1783793093000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Patient-derived model capturing hypoxia and extracellular matrix remodelling of immunologically cold high-grade serous tumours"],"prefix":"10.1038","volume":"17","author":[{"given":"Simona","family":"Plesselova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailey","family":"Axemaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Calar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oduduabasi","family":"Isaiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Wollman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somshuvra","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5338-084X","authenticated-orcid":false,"given":"Etienne Z.","family":"Gnimpieba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darci M.","family":"Fink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congzhou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiruni","family":"Sumanasiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina W.","family":"Thiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5953-1197","authenticated-orcid":false,"given":"Pilar","family":"de la Puente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"75262_CR1","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/nrc4019","volume":"15","author":"DD Bowtell","year":"2015","unstructured":"Bowtell, D. D. et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat. Rev. Cancer 15, 668\u2013679 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"75262_CR2","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s42003-023-05026-3","volume":"6","author":"EN Kotnik","year":"2023","unstructured":"Kotnik, E. N. et al. Genetic characterization of primary and metastatic high-grade serous ovarian cancer tumors reveals distinct features associated with survival. Commun. Biol. 6, 688 (2023).","journal-title":"Commun. Biol."},{"key":"75262_CR3","doi-asserted-by":"publisher","first-page":"3476","DOI":"10.1016\/j.cell.2023.07.004","volume":"186","author":"S Chowdhury","year":"2023","unstructured":"Chowdhury, S. et al. Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer. Cell 186, 3476\u20133498 e3435 (2023).","journal-title":"Cell"},{"key":"75262_CR4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa020177","volume":"348","author":"L Zhang","year":"2003","unstructured":"Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203\u2013213 (2003).","journal-title":"N. Engl. J. Med."},{"key":"75262_CR5","doi-asserted-by":"publisher","first-page":"175883592096724","DOI":"10.1177\/1758835920967241","volume":"12","author":"J Hao","year":"2020","unstructured":"Hao, J., Yu, H., Zhang, T., An, R. & Xue, Y. Prognostic impact of tumor-infiltrating lymphocytes in high grade serous ovarian cancer: a systematic review and meta-analysis. Ther. Adv. Med. Oncol. 12, 1758835920967241 (2020).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"75262_CR6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3290","volume":"3","author":"EL Goode","year":"2017","unstructured":"Goode, E. L. et al. Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer. JAMA Oncol. 3, e173290 (2017).","journal-title":"JAMA Oncol."},{"key":"75262_CR7","doi-asserted-by":"crossref","unstructured":"Boudreau, J. E. Immune-molecular interactions in high-grade serous ovarian cancer distinguish long-term survivors. J. Clin. Invest. 134, e184790 (2024).","DOI":"10.1172\/JCI184790"},{"key":"75262_CR8","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1038\/s41588-022-01230-9","volume":"54","author":"DW Garsed","year":"2022","unstructured":"Garsed, D. W. et al. The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer. Nat. Genet. 54, 1853\u20131864 (2022).","journal-title":"Nat. Genet."},{"key":"75262_CR9","unstructured":"Nelson, B. H. et al. Immunological and molecular features of the tumor microenvironment of long-term survivors of ovarian cancer. J. Clin. Invest. 134, e179501 (2024)."},{"key":"75262_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-019-1051-3","volume":"19","author":"H Guo","year":"2019","unstructured":"Guo, H. et al. Cancer-associated fibroblast-derived exosomal microRNA-98-5p promotes cisplatin resistance in ovarian cancer by targeting CDKN1A. Cancer Cell Int. 19, 347 (2019).","journal-title":"Cancer Cell Int."},{"key":"75262_CR11","doi-asserted-by":"publisher","first-page":"115425","DOI":"10.1016\/j.biopha.2023.115425","volume":"166","author":"Z Zhao","year":"2023","unstructured":"Zhao, Z., Li, T., Sun, L., Yuan, Y. & Zhu, Y. Potential mechanisms of cancer-associated fibroblasts in therapeutic resistance. Biomed. Pharmacother. 166, 115425 (2023).","journal-title":"Biomed. Pharmacother."},{"key":"75262_CR12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1083\/jcb.201102147","volume":"196","author":"P Lu","year":"2012","unstructured":"Lu, P., Weaver, V. M. & Werb, Z. The extracellular matrix: a dynamic niche in cancer progression. J. Cell Biol. 196, 395\u2013406 (2012).","journal-title":"J. Cell Biol."},{"key":"75262_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215839","volume":"546","author":"Y Fang","year":"2022","unstructured":"Fang, Y. et al. Cancer-associated fibroblast-like fibroblasts in vocal fold leukoplakia suppress CD8(+)T cell functions by inducing IL-6 autocrine loop and interacting with Th17 cells. Cancer Lett. 546, 215839 (2022).","journal-title":"Cancer Lett."},{"key":"75262_CR14","doi-asserted-by":"publisher","first-page":"5016","DOI":"10.1158\/0008-5472.CAN-13-0023","volume":"73","author":"TL Yeung","year":"2013","unstructured":"Yeung, T. L. et al. TGF-beta modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer Res. 73, 5016\u20135028 (2013).","journal-title":"Cancer Res."},{"key":"75262_CR15","doi-asserted-by":"crossref","unstructured":"Zhang, M., Chen, Z., Wang, Y., Zhao, H. & Du, Y. The role of cancer-associated fibroblasts in ovarian cancer. Cancers 14, 2637 (2022).","DOI":"10.3390\/cancers14112637"},{"key":"75262_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-8-223","volume":"8","author":"KL Sodek","year":"2008","unstructured":"Sodek, K. L., Brown, T. J. & Ringuette, M. J. Collagen I but not matrigel matrices provide an MMP-dependent barrier to ovarian cancer cell penetration. BMC Cancer 8, 223 (2008).","journal-title":"BMC Cancer"},{"key":"75262_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-020-00646-x","volume":"18","author":"H Song","year":"2020","unstructured":"Song, H. et al. Three-dimensional culture and clinical drug responses of a highly metastatic human ovarian cancer HO-8910PM cells in nanofibrous microenvironments of three hydrogel biomaterials. J. Nanobiotechnol. 18, 90 (2020).","journal-title":"J. Nanobiotechnol."},{"key":"75262_CR18","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/s41596-021-00652-9","volume":"17","author":"C Loebel","year":"2022","unstructured":"Loebel, C. et al. Metabolic labeling of secreted matrix to investigate cell-material interactions in tissue engineering and mechanobiology. Nat. Protoc. 17, 618\u2013648 (2022).","journal-title":"Nat. Protoc."},{"key":"75262_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38093-5","volume":"14","author":"EH Puttock","year":"2023","unstructured":"Puttock, E. H. et al. Extracellular matrix educates an immunoregulatory tumor macrophage phenotype found in ovarian cancer metastasis. Nat. Commun. 14, 2514 (2023).","journal-title":"Nat. Commun."},{"key":"75262_CR20","doi-asserted-by":"crossref","unstructured":"Klemba, A. et al. Hypoxia-mediated decrease of ovarian cancer cells reaction to treatment: significance for chemo- and immunotherapies. Int. J. Mol. Sci. 21, 9492 (2020).","DOI":"10.3390\/ijms21249492"},{"key":"75262_CR21","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1016\/j.celrep.2017.08.071","volume":"20","author":"Y Gropper","year":"2017","unstructured":"Gropper, Y. et al. Culturing CTLs under hypoxic conditions enhances their cytolysis and improves their anti-tumor function. Cell Rep. 20, 2547\u20132555 (2017).","journal-title":"Cell Rep."},{"key":"75262_CR22","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1148\/radiol.2018180666","volume":"289","author":"S Nandy","year":"2018","unstructured":"Nandy, S. et al. Evaluation of ovarian cancer: initial application of coregistered photoacoustic tomography and US. Radiology 289, 740\u2013747 (2018).","journal-title":"Radiology"},{"key":"75262_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14052-x","volume":"11","author":"V Bhandari","year":"2020","unstructured":"Bhandari, V., Li, C. H., Bristow, R. G., Boutros, P. C. & Consortium, P. Divergent mutational processes distinguish hypoxic and normoxic tumours. Nat. Commun. 11, 737 (2020).","journal-title":"Nat. Commun."},{"key":"75262_CR24","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1002\/ijc.24601","volume":"125","author":"K Selvendiran","year":"2009","unstructured":"Selvendiran, K. et al. Hypoxia induces chemoresistance in ovarian cancer cells by activation of signal transducer and activator of transcription 3. Int. J. Cancer 125, 2198\u20132204 (2009).","journal-title":"Int. J. Cancer"},{"key":"75262_CR25","doi-asserted-by":"publisher","first-page":"20130676","DOI":"10.1259\/bjr.20130676","volume":"87","author":"SR McKeown","year":"2014","unstructured":"McKeown, S. R. Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response. Br. J. Radio. 87, 20130676 (2014).","journal-title":"Br. J. Radio."},{"key":"75262_CR26","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.matbio.2023.02.004","volume":"118","author":"Y Brown","year":"2023","unstructured":"Brown, Y., Hua, S. & Tanwar, P. S. Extracellular matrix in high-grade serous ovarian cancer: advances in understanding of carcinogenesis and cancer biology. Matrix Biol. 118, 16\u201346 (2023).","journal-title":"Matrix Biol."},{"key":"75262_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1530\/jrf.0.0330011","volume":"33","author":"IS Fraser","year":"1973","unstructured":"Fraser, I. S., Baird, D. T. & Cockburn, F. Ovarian venous blood PO 2, PCO 2 and pH in women. J. Reprod. Fertil. 33, 11\u201317 (1973).","journal-title":"J. Reprod. Fertil."},{"key":"75262_CR28","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0015-0282(16)55635-0","volume":"59","author":"DA Imoedemhe","year":"1993","unstructured":"Imoedemhe, D. A., Chan, R. C., Ramadan, I. A. & Sigue, A. B. Changes in follicular fluid gas and pH during carbon dioxide pneumoperitoneum for laparoscopic aspiration and their effect on human oocyte fertilizability. Fertil. Steril. 59, 177\u2013182 (1993).","journal-title":"Fertil. Steril."},{"key":"75262_CR29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/0028-2243(92)90241-P","volume":"43","author":"B Fischer","year":"1992","unstructured":"Fischer, B., Kunzel, W., Kleinstein, J. & Gips, H. Oxygen tension in follicular fluid falls with follicle maturation. Eur. J. Obstet. Gynecol. Reprod. Biol. 43, 39\u201343 (1992).","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"75262_CR30","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.3389\/fbioe.2020.01040","volume":"8","author":"S Bhattacharya","year":"2020","unstructured":"Bhattacharya, S., Calar, K., Evans, C., Petrasko, M. & de la Puente, P. Bioengineering the oxygen-deprived tumor microenvironment within a three-dimensional platform for studying tumor-immune interactions. Front. Bioeng. Biotechnol. 8, 1040 (2020).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"75262_CR31","doi-asserted-by":"crossref","unstructured":"Calar, K., Plesselova, S., Bhattacharya, S., Jorgensen, M. & de la Puente, P. Human plasma-derived 3D cultures model breast cancer treatment responses and predict clinically effective drug treatment concentrations. Cancers 12, 1722 (2020).","DOI":"10.3390\/cancers12071722"},{"key":"75262_CR32","doi-asserted-by":"publisher","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-08-0196","volume":"14","author":"RW Tothill","year":"2008","unstructured":"Tothill, R. W. et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin. Cancer Res. 14, 5198\u20135208 (2008).","journal-title":"Clin. Cancer Res"},{"key":"75262_CR33","doi-asserted-by":"publisher","first-page":"4156187","DOI":"10.1155\/2021\/4156187","volume":"2021","author":"C Wei","year":"2021","unstructured":"Wei, C., Liu, X., Wang, Q., Li, Q. & Xie, M. Identification of hypoxia signature to assess the tumor immune microenvironment and predict prognosis in patients with ovarian cancer. Int. J. Endocrinol. 2021, 4156187 (2021).","journal-title":"Int. J. Endocrinol."},{"key":"75262_CR34","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/s12957-021-02440-x","volume":"19","author":"W Li","year":"2021","unstructured":"Li, W., Ma, J. A., Sheng, X. & Xiao, C. Screening of CXC chemokines in the microenvironment of ovarian cancer and the biological function of CXCL10. World J. Surg. Oncol. 19, 329 (2021).","journal-title":"World J. Surg. Oncol."},{"key":"75262_CR35","doi-asserted-by":"crossref","unstructured":"Mallikarjuna, P., Zhou, Y. & Landstrom, M. The synergistic cooperation between TGF-beta and hypoxia in cancer and fibrosis. Biomolecules 12, 635 (2022).","DOI":"10.3390\/biom12050635"},{"key":"75262_CR36","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41580-018-0007-0","volume":"19","author":"CJ David","year":"2018","unstructured":"David, C. J. & Massague, J. Contextual determinants of TGFbeta action in development, immunity and cancer. Nat. Rev. Mol. Cell Biol. 19, 419\u2013435 (2018).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"75262_CR37","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1016\/j.cell.2023.07.036","volume":"186","author":"J Massague","year":"2023","unstructured":"Massague, J. & Sheppard, D. TGF-beta signaling in health and disease. Cell 186, 4007\u20134037 (2023).","journal-title":"Cell"},{"key":"75262_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19408-2","volume":"11","author":"M Desbois","year":"2020","unstructured":"Desbois, M. et al. Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer. Nat. Commun. 11, 5583 (2020).","journal-title":"Nat. Commun."},{"key":"75262_CR39","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40425-019-0556-6","volume":"7","author":"DE Kuczek","year":"2019","unstructured":"Kuczek, D. E. et al. Collagen density regulates the activity of tumor-infiltrating T cells. J. Immunother. Cancer 7, 68 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"75262_CR40","doi-asserted-by":"crossref","unstructured":"Xue, B. et al. A novel hydrogel-based 3D in vitro tumor panel of 30 PDX models incorporates tumor, stromal and immune cell compartments of the tme for the screening of oncology and immuno-therapies. Cells 12, 1145 (2023).","DOI":"10.3390\/cells12081145"},{"key":"75262_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1189","volume":"13","author":"S Zheng","year":"2023","unstructured":"Zheng, S. et al. Dissecting the role of cancer-associated fibroblast-derived biglycan as a potential therapeutic target in immunotherapy resistance: a tumor bulk and single-cell transcriptomic study. Clin. Transl. Med. 13, e1189 (2023).","journal-title":"Clin. Transl. Med."},{"key":"75262_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-017-0011-9","volume":"7","author":"V Petrova","year":"2018","unstructured":"Petrova, V., Annicchiarico-Petruzzelli, M., Melino, G. & Amelio, I. The hypoxic tumour microenvironment. Oncogenesis 7, 10 (2018).","journal-title":"Oncogenesis"},{"key":"75262_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117601","volume":"180","author":"L Svajda","year":"2024","unstructured":"Svajda, L. et al. Targeting hypoxia in combination with paclitaxel to enhance therapeutic efficacy in breast and ovarian cancer. Biomed. Pharmacother. 180, 117601 (2024).","journal-title":"Biomed. Pharmacother."},{"key":"75262_CR44","doi-asserted-by":"crossref","unstructured":"Synowiec, A. et al. Hypoxia, but not normoxia, reduces effects of resveratrol on cisplatin treatment in A2780 ovarian cancer cells: a challenge for resveratrol use in anticancer adjuvant cisplatin therapy. Int. J. Mol. Sci. 24, 5715 (2023).","DOI":"10.3390\/ijms24065715"},{"key":"75262_CR45","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/s42003-022-03495-6","volume":"5","author":"B Horst","year":"2022","unstructured":"Horst, B. et al. Hypoxia-induced inhibin promotes tumor growth and vascular permeability in ovarian cancers. Commun. Biol. 5, 536 (2022).","journal-title":"Commun. Biol."},{"key":"75262_CR46","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1093\/humrep\/dead122","volume":"38","author":"F Vitale","year":"2023","unstructured":"Vitale, F. et al. Importance of oxygen tension in human ovarian tissue in vitro culture. Hum. Reprod. 38, 1538\u20131546 (2023).","journal-title":"Hum. Reprod."},{"key":"75262_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18794-x","volume":"11","author":"J Winkler","year":"2020","unstructured":"Winkler, J., Abisoye-Ogunniyan, A., Metcalf, K. J. & Werb, Z. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat. Commun. 11, 5120 (2020).","journal-title":"Nat. Commun."},{"key":"75262_CR48","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.trecan.2024.09.001","volume":"10","author":"BS Chap","year":"2024","unstructured":"Chap, B. S., Rayroux, N., Grimm, A. J., Ghisoni, E. & Dangaj Laniti, D. Crosstalk of T cells within the ovarian cancer microenvironment. Trends Cancer 10, 1116\u20131130 (2024).","journal-title":"Trends Cancer"},{"key":"75262_CR49","doi-asserted-by":"crossref","unstructured":"Belotti, Y., Lim, E. H. & Lim, C. T. The role of the extracellular matrix and tumor-infiltrating immune cells in the prognostication of high-grade serous ovarian cancer. Cancers 14, 404 (2022).","DOI":"10.3390\/cancers14020404"},{"key":"75262_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.106381","volume":"26","author":"C Pinto","year":"2023","unstructured":"Pinto, C. et al. Tumor microenvironment mimicking 3D models unveil the multifaceted effects of SMAC mimetics. iScience 26, 106381 (2023).","journal-title":"iScience"},{"key":"75262_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-15583-3","volume":"7","author":"Y Ando","year":"2017","unstructured":"Ando, Y. et al. A microdevice platform recapitulating hypoxic tumor microenvironments. Sci. Rep. 7, 15233 (2017).","journal-title":"Sci. Rep."},{"key":"75262_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60395-z","volume":"16","author":"NJ Schork","year":"2025","unstructured":"Schork, N. J. & Goetz, L. H. From precision interventions to precision health. Nat. Commun. 16, 5024 (2025).","journal-title":"Nat. Commun."},{"key":"75262_CR53","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1158\/0008-5472.CAN-18-2616","volume":"79","author":"S Natarajan","year":"2019","unstructured":"Natarajan, S. et al. Collagen remodeling in the hypoxic tumor-mesothelial niche promotes ovarian cancer metastasis. Cancer Res. 79, 2271\u20132284 (2019).","journal-title":"Cancer Res"},{"key":"75262_CR54","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1365-2249.2007.03565.x","volume":"151","author":"M Mikko","year":"2008","unstructured":"Mikko, M. et al. Human T cells stimulate fibroblast-mediated degradation of extracellular matrix in vitro. Clin. Exp. Immunol. 151, 317\u2013325 (2008).","journal-title":"Clin. Exp. Immunol."},{"key":"75262_CR55","doi-asserted-by":"publisher","first-page":"26065","DOI":"10.18632\/oncotarget.4569","volume":"6","author":"Z Ou","year":"2015","unstructured":"Ou, Z. et al. Tumor microenvironment B cells increase bladder cancer metastasis via modulation of the IL-8\/androgen receptor (AR)\/MMPs signals. Oncotarget 6, 26065\u201326078 (2015).","journal-title":"Oncotarget"},{"key":"75262_CR56","first-page":"2811","volume":"34","author":"M Duechler","year":"2014","unstructured":"Duechler, M., Peczek, L., Szubert, M. & Suzin, J. Influence of hypoxia inducible factors on the immune microenvironment in ovarian cancer. Anticancer Res. 34, 2811\u20132819 (2014).","journal-title":"Anticancer Res."},{"key":"75262_CR57","doi-asserted-by":"publisher","first-page":"1450751","DOI":"10.3389\/fphar.2024.1450751","volume":"15","author":"Q Chen","year":"2024","unstructured":"Chen, Q., Zhang, Y., Wang, C., Ding, H. & Chi, L. Integrated analysis of single-cell and bulk transcriptome reveals hypoxia-induced immunosuppressive microenvironment to predict immunotherapy response in high-grade serous ovarian cancer. Front. Pharm. 15, 1450751 (2024).","journal-title":"Front. Pharm."},{"key":"75262_CR58","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2326-6066.CIR-20-0561","volume":"9","author":"P Velica","year":"2021","unstructured":"Velica, P. et al. Modified hypoxia-inducible factor expression in CD8(+) T cells increases antitumor efficacy. Cancer Immunol. Res. 9, 401\u2013414 (2021).","journal-title":"Cancer Immunol. Res."},{"key":"75262_CR59","doi-asserted-by":"crossref","unstructured":"Liikanen, I. et al. Hypoxia-inducible factor activity promotes antitumor effector function and tissue residency by CD8+ T cells. J. Clin. Invest. 131, e143729 (2021).","DOI":"10.1172\/JCI143729"},{"key":"75262_CR60","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","volume":"175","author":"M Sade-Feldman","year":"2018","unstructured":"Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175, 998\u20131013.e1020 (2018).","journal-title":"Cell"},{"key":"75262_CR61","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller, B. C. et al. Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade. Nat. Immunol. 20, 326\u2013336 (2019).","journal-title":"Nat. Immunol."},{"key":"75262_CR62","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ygyno.2025.01.010","volume":"193","author":"S Corvigno","year":"2025","unstructured":"Corvigno, S. et al. High prevalence of FAP+ cancer-associated fibroblasts predicts poor outcome in patients with high-grade serous ovarian cancer with high CD8 T-cell density. Gynecol. Oncol. 193, 148\u2013155 (2025).","journal-title":"Gynecol. Oncol."},{"key":"75262_CR63","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s42003-024-05826-1","volume":"7","author":"C Chai","year":"2024","unstructured":"Chai, C. et al. Single-cell transcriptome analysis of epithelial, immune, and stromal signatures and interactions in human ovarian cancer. Commun. Biol. 7, 131 (2024).","journal-title":"Commun. Biol."},{"key":"75262_CR64","doi-asserted-by":"publisher","first-page":"1434617","DOI":"10.3389\/fvets.2024.1434617","volume":"11","author":"MC Kim","year":"2024","unstructured":"Kim, M. C., Borcherding, N., Song, W. J., Kolb, R. & Zhang, W. Leveraging single-cell transcriptomic data to uncover immune suppressive cancer cell subsets in triple-negative canine breast cancers. Front. Vet. Sci. 11, 1434617 (2024).","journal-title":"Front. Vet. Sci."},{"key":"75262_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2020.118663","volume":"1867","author":"F Baltes","year":"2020","unstructured":"Baltes, F. et al. beta(1)-Integrin binding to collagen type 1 transmits breast cancer cells into chemoresistance by activating ABC efflux transporters. Biochim. Biophys. Acta Mol. Cell Res. 1867, 118663 (2020).","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"75262_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06070-9","volume":"23","author":"Y Yang","year":"2025","unstructured":"Yang, Y. et al. Tumor-associated-fibrosis and active collagen-CD44 axis characterize a poor-prognosis subtype of gastric cancer and contribute to tumor immunosuppression. J. Transl. Med. 23, 123 (2025).","journal-title":"J. Transl. Med."},{"key":"75262_CR67","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41392-024-01764-w","volume":"9","author":"Z Deng","year":"2024","unstructured":"Deng, Z. et al. TGF-beta signaling in health, disease, and therapeutics. Signal Transduct. Target Ther. 9, 61 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"75262_CR68","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s40425-018-0356-4","volume":"6","author":"RB Holmgaard","year":"2018","unstructured":"Holmgaard, R. B. et al. Targeting the TGFbeta pathway with galunisertib, a TGFbetaRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade. J. Immunother. Cancer 6, 47 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"75262_CR69","doi-asserted-by":"crossref","unstructured":"Zhang, Q. et al. LY2157299 monohydrate, a TGF-betaR1 inhibitor, suppresses tumor growth and ascites development in ovarian cancer. Cancers 10, 280 (2018).","DOI":"10.3390\/cancers10080260"},{"key":"75262_CR70","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.cytogfr.2023.04.001","volume":"71-72","author":"M Turati","year":"2023","unstructured":"Turati, M., Mousset, A., Issa, N., Turtoi, A. & Ronca, R. TGF-beta mediated drug resistance in solid cancer. Cytokine Growth Factor Rev. 71-72, 54\u201365 (2023).","journal-title":"Cytokine Growth Factor Rev."},{"key":"75262_CR71","doi-asserted-by":"crossref","unstructured":"Melisi, D. et al. Safety and activity of the TGF\u03b2 receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. J. Immunother. Cancer 9, e002068 (2021).","DOI":"10.1136\/jitc-2020-002068"},{"key":"75262_CR72","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1158\/1535-7163.MCT-18-0850","volume":"18","author":"DR Principe","year":"2019","unstructured":"Principe, D. R. et al. TGFbeta blockade augments PD-1 inhibition to promote T-cell-mediated regression of pancreatic cancer. Mol. Cancer Ther. 18, 613\u2013620 (2019).","journal-title":"Mol. Cancer Ther."},{"key":"75262_CR73","doi-asserted-by":"crossref","unstructured":"Peterson, J. M. et al. Galunisertib exerts antifibrotic effects on TGF-\u03b2-induced fibroproliferative dermal fibroblasts. Int. J. Mol. Sci. 23, 6689 (2022).","DOI":"10.3390\/ijms23126689"},{"key":"75262_CR74","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41392-020-00436-9","volume":"6","author":"S Liu","year":"2021","unstructured":"Liu, S., Ren, J. & Ten Dijke, P. Targeting TGFbeta signal transduction for cancer therapy. Signal Transduct. Target Ther. 6, 8 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"75262_CR75","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1111\/bph.13945","volume":"174","author":"T Luangmonkong","year":"2017","unstructured":"Luangmonkong, T. et al. Evaluating the antifibrotic potency of galunisertib in a human ex vivo model of liver fibrosis. Br. J. Pharm. 174, 3107\u20133117 (2017).","journal-title":"Br. J. Pharm."},{"key":"75262_CR76","doi-asserted-by":"publisher","first-page":"23102","DOI":"10.18632\/oncotarget.24562","volume":"9","author":"C Zhou","year":"2018","unstructured":"Zhou, C. et al. A targeted transforming growth factor-beta (TGF-beta) blocker, TTB, inhibits tumor growth and metastasis. Oncotarget 9, 23102\u201323113 (2018).","journal-title":"Oncotarget"},{"key":"75262_CR77","doi-asserted-by":"publisher","first-page":"21614","DOI":"10.18632\/oncotarget.4308","volume":"6","author":"M Serova","year":"2015","unstructured":"Serova, M. et al. Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients. Oncotarget 6, 21614\u201321627 (2015).","journal-title":"Oncotarget"},{"key":"75262_CR78","doi-asserted-by":"crossref","unstructured":"Akhurst, R. J. Targeting TGF-beta signaling for therapeutic gain. Cold Spring Harb. Perspect. Biol. 9, a022301 (2017).","DOI":"10.1101\/cshperspect.a022301"},{"key":"75262_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-018-0232-3","volume":"16","author":"Z Qin","year":"2018","unstructured":"Qin, Z., Xia, W., Fisher, G. J., Voorhees, J. J. & Quan, T. YAP\/TAZ regulates TGF-beta\/Smad3 signaling by induction of Smad7 via AP-1 in human skin dermal fibroblasts. Cell Commun. Signal 16, 18 (2018).","journal-title":"Cell Commun. Signal"},{"key":"75262_CR80","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"75262_CR81","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nature25492","volume":"554","author":"DVF Tauriello","year":"2018","unstructured":"Tauriello, D. V. F. et al. TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis. Nature 554, 538\u2013543 (2018).","journal-title":"Nature"},{"key":"75262_CR82","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nri2216","volume":"8","author":"L Zitvogel","year":"2008","unstructured":"Zitvogel, L., Apetoh, L., Ghiringhelli, F. & Kroemer, G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8, 59\u201373 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"75262_CR83","doi-asserted-by":"crossref","unstructured":"Axemaker H. et al. Reprogramming of normal fibroblasts into ovarian cancer-associated fibroblasts via non-vesicular paracrine signaling induces an activated fibroblast phenotype. Biochim Biophys Acta Mol Cell Res. 1871, 119801 (2024).","DOI":"10.1016\/j.bbamcr.2024.119801"},{"key":"75262_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2021.100553","volume":"2","author":"T Yasuda","year":"2021","unstructured":"Yasuda, T. et al. Protocol to establish cancer-associated fibroblasts from surgically resected tissues and generate senescent fibroblasts. STAR Protoc. 2, 100553 (2021).","journal-title":"STAR Protoc."},{"key":"75262_CR85","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01744-8","volume":"22","author":"Z Yuan","year":"2023","unstructured":"Yuan, Z. et al. Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments. Mol. Cancer 22, 48 (2023).","journal-title":"Mol. Cancer"},{"key":"75262_CR86","doi-asserted-by":"publisher","first-page":"5329","DOI":"10.21873\/anticanres.14540","volume":"40","author":"YM Morillon 2nd","year":"2020","unstructured":"Morillon, Y. M. 2nd, Sabzevari, A., Schlom, J. & Greiner, J. W. The development of next-generation PBMC humanized mice for preclinical investigation of cancer immunotherapeutic agents. Anticancer Res. 40, 5329\u20135341 (2020).","journal-title":"Anticancer Res."},{"key":"75262_CR87","first-page":"15 21 11","volume":"Chapter 15","author":"T Pearson","year":"2008","unstructured":"Pearson, T., Greiner, D. L. & Shultz, L. D. Creation of \u201chumanized\u201d mice to study human immunity. Curr. Protoc. Immunol. Chapter 15, 15 21 11\u201315 21 21 (2008).","journal-title":"Curr. Protoc. Immunol."},{"key":"75262_CR88","doi-asserted-by":"publisher","first-page":"617","DOI":"10.12688\/f1000research.10990.1","volume":"6","author":"EW Petersdorf","year":"2017","unstructured":"Petersdorf, E. W. Role of major histocompatibility complex variation in graft-versus-host disease after hematopoietic cell transplantation. F1000Res 6, 617 (2017).","journal-title":"F1000Res"},{"key":"75262_CR89","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41416-023-02471-z","volume":"130","author":"ZL Arter","year":"2024","unstructured":"Arter, Z. L. et al. Epithelial ovarian cancer survival by race and ethnicity in an equal-access healthcare population. Br. J. Cancer 130, 108\u2013113 (2024).","journal-title":"Br. J. Cancer"},{"key":"75262_CR90","doi-asserted-by":"crossref","unstructured":"Plesselova, S. et al. Multicompartmentalized microvascularized tumor-on-a-chip to study tumor-stroma interactions and drug resistance in ovarian cancer. Cell. Mol. Bioeng. 17, 345\u2013367 (2024).","DOI":"10.1007\/s12195-024-00817-y"},{"key":"75262_CR91","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41392-021-00544-0","volume":"6","author":"J Huang","year":"2021","unstructured":"Huang, J. et al. Extracellular matrix and its therapeutic potential for cancer treatment. Signal Transduct. Target Ther. 6, 153 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"75262_CR92","doi-asserted-by":"publisher","first-page":"23720","DOI":"10.18632\/oncotarget.4690","volume":"6","author":"AB Nagaraj","year":"2015","unstructured":"Nagaraj, A. B. et al. Critical role of Wnt\/beta-catenin signaling in driving epithelial ovarian cancer platinum resistance. Oncotarget 6, 23720\u201323734 (2015).","journal-title":"Oncotarget"},{"key":"75262_CR93","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14049","volume":"8","author":"GX Zheng","year":"2017","unstructured":"Zheng, G. X. et al. Massively parallel digital transcriptional profiling of single cells. Nat. Commun. 8, 14049 (2017).","journal-title":"Nat. Commun."},{"key":"75262_CR94","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888\u20131902 e1821 (2019).","journal-title":"Cell"},{"key":"75262_CR95","doi-asserted-by":"crossref","unstructured":"Becht, E. et al. Dimensionality reduction for visualizing single-cell data using UMAP. Nat. Biotechnol. 37, 38\u201344 (2019).","DOI":"10.1038\/nbt.4314"},{"key":"75262_CR96","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/s41586-019-0969-x","volume":"566","author":"J Cao","year":"2019","unstructured":"Cao, J. et al. The single-cell transcriptional landscape of mammalian organogenesis. Nature 566, 496\u2013502 (2019).","journal-title":"Nature"},{"key":"75262_CR97","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41590-018-0276-y","volume":"20","author":"D Aran","year":"2019","unstructured":"Aran, D. et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat. Immunol. 20, 163\u2013172 (2019).","journal-title":"Nat. Immunol."},{"key":"75262_CR98","doi-asserted-by":"publisher","first-page":"e0206785","DOI":"10.1371\/journal.pone.0206785","volume":"13","author":"AJ Shih","year":"2018","unstructured":"Shih, A. J. et al. Identification of grade and origin specific cell populations in serous epithelial ovarian cancer by single cell RNA-seq. PLoS ONE 13, e0206785 (2018).","journal-title":"PLoS ONE"},{"key":"75262_CR99","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-022-00991-4","volume":"20","author":"RF Carvalho","year":"2022","unstructured":"Carvalho, R. F. et al. Single-cell and bulk RNA sequencing reveal ligands and receptors associated with worse overall survival in serous ovarian cancer. Cell Commun. Signal. 20, 176 (2022).","journal-title":"Cell Commun. Signal."},{"key":"75262_CR100","doi-asserted-by":"crossref","unstructured":"Izzi, V., Davis, M. N. & Naba, A. Pan-cancer analysis of the genomic alterations and mutations of the matrisome. Cancers 12, 2046 (2020).","DOI":"10.3390\/cancers12082046"},{"key":"75262_CR101","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.951582","volume":"13","author":"S Feng","year":"2022","unstructured":"Feng, S. et al. Integrative analysis from multicenter studies identifies a WGCNA-derived cancer-associated fibroblast signature for ovarian cancer. Front. Immunol. 13, 951582 (2022).","journal-title":"Front. Immunol."},{"key":"75262_CR102","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06654-8","volume":"9","author":"A Chakravarthy","year":"2018","unstructured":"Chakravarthy, A., Khan, L., Bensler, N. P., Bose, P. & De Carvalho, D. D. TGF-beta-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure. Nat. Commun. 9, 4692 (2018).","journal-title":"Nat. Commun."},{"key":"75262_CR103","doi-asserted-by":"publisher","first-page":"109165","DOI":"10.1016\/j.celrep.2021.109165","volume":"35","author":"S Olalekan","year":"2021","unstructured":"Olalekan, S., Xie, B., Back, R., Eckart, H. & Basu, A. Characterizing the tumor microenvironment of metastatic ovarian cancer by single-cell transcriptomics. Cell Rep. 35, 109165 (2021).","journal-title":"Cell Rep."},{"key":"75262_CR104","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21246-9","volume":"12","author":"S Jin","year":"2021","unstructured":"Jin, S. et al. Inference and analysis of cell-cell communication using CellChat. Nat. Commun. 12, 1088 (2021).","journal-title":"Nat. Commun."},{"key":"75262_CR105","doi-asserted-by":"crossref","unstructured":"Lord, S. J., Velle, K. B., Mullins, R. D. & Fritz-Laylin, L. K. SuperPlots: communicating reproducibility and variability in cell biology. J. Cell Biol. 219, e202001064 (2020).","DOI":"10.1083\/jcb.202001064"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75262-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75262-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75262-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:19:07Z","timestamp":1787015947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75262-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":105,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["75262"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-75262-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"7 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Pilar de la Puente, Somshuvra Bhattacharya, and Kristin Calar have a patent for plasma-derived 3D cultures, US Patent Application #2022\/0228124. Pilar de la Puente is the co-founder of Cellatrix LLC; however, there has been no contribution from the aforementioned. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"8568"}}